Table of Content

1 Pneumonia Vaccine Market Overview
1.1 Product Overview and Scope of Pneumonia Vaccine
1.2 Pneumonia Vaccine Segment by Type
1.2.1 Global Pneumonia Vaccine Market Value Comparison by Type (2024-2034)
1.2.2 Pneumococcal Conjugate Vaccine (PCV13)
1.2.3 Pneumococcal Polysaccharide Vaccine (PPSV23)
1.2.4 Other
1.3 Pneumonia Vaccine Segment by Application
1.3.1 Global Pneumonia Vaccine Market Value by Application: (2024-2034)
1.3.2 Pneumonia
1.3.3 Meningitis
1.3.4 Sepsis
1.4 Global Pneumonia Vaccine Market Size Estimates and Forecasts
1.4.1 Global Pneumonia Vaccine Revenue 2018-2034
1.4.2 Global Pneumonia Vaccine Sales 2018-2034
1.4.3 Global Pneumonia Vaccine Market Average Price (2018-2034)
1.5 Assumptions and Limitations
2 Pneumonia Vaccine Market Competition by Manufacturers
2.1 Global Pneumonia Vaccine Sales Market Share by Manufacturers (2018-2023)
2.2 Global Pneumonia Vaccine Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Pneumonia Vaccine Average Price by Manufacturers (2018-2023)
2.4 Global Pneumonia Vaccine Industry Ranking 2021 VS 2024 VS 2023
2.5 Global Key Manufacturers of Pneumonia Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Pneumonia Vaccine, Product Type & Application
2.7 Pneumonia Vaccine Market Competitive Situation and Trends
2.7.1 Pneumonia Vaccine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Pneumonia Vaccine Players Market Share by Revenue
2.7.3 Global Pneumonia Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Pneumonia Vaccine Retrospective Market Scenario by Region
3.1 Global Pneumonia Vaccine Market Size by Region: 2018 Versus 2024 Versus 2034
3.2 Global Pneumonia Vaccine Global Pneumonia Vaccine Sales by Region: 2018-2034
3.2.1 Global Pneumonia Vaccine Sales by Region: 2018-2023
3.2.2 Global Pneumonia Vaccine Sales by Region: 2024-2034
3.3 Global Pneumonia Vaccine Global Pneumonia Vaccine Revenue by Region: 2018-2034
3.3.1 Global Pneumonia Vaccine Revenue by Region: 2018-2023
3.3.2 Global Pneumonia Vaccine Revenue by Region: 2024-2034
3.4 North America Pneumonia Vaccine Market Facts & Figures by Country
3.4.1 North America Pneumonia Vaccine Market Size by Country: 2018 VS 2024 VS 2034
3.4.2 North America Pneumonia Vaccine Sales by Country (2018-2034)
3.4.3 North America Pneumonia Vaccine Revenue by Country (2018-2034)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Pneumonia Vaccine Market Facts & Figures by Country
3.5.1 Europe Pneumonia Vaccine Market Size by Country: 2018 VS 2024 VS 2034
3.5.2 Europe Pneumonia Vaccine Sales by Country (2018-2034)
3.5.3 Europe Pneumonia Vaccine Revenue by Country (2018-2034)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Pneumonia Vaccine Market Facts & Figures by Country
3.6.1 Asia Pacific Pneumonia Vaccine Market Size by Country: 2018 VS 2024 VS 2034
3.6.2 Asia Pacific Pneumonia Vaccine Sales by Country (2018-2034)
3.6.3 Asia Pacific Pneumonia Vaccine Revenue by Country (2018-2034)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Pneumonia Vaccine Market Facts & Figures by Country
3.7.1 Latin America Pneumonia Vaccine Market Size by Country: 2018 VS 2024 VS 2034
3.7.2 Latin America Pneumonia Vaccine Sales by Country (2018-2034)
3.7.3 Latin America Pneumonia Vaccine Revenue by Country (2018-2034)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Pneumonia Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Pneumonia Vaccine Market Size by Country: 2018 VS 2024 VS 2034
3.8.2 Middle East and Africa Pneumonia Vaccine Sales by Country (2018-2034)
3.8.3 Middle East and Africa Pneumonia Vaccine Revenue by Country (2018-2034)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Pneumonia Vaccine Sales by Type (2018-2034)
4.1.1 Global Pneumonia Vaccine Sales by Type (2018-2023)
4.1.2 Global Pneumonia Vaccine Sales by Type (2024-2034)
4.1.3 Global Pneumonia Vaccine Sales Market Share by Type (2018-2034)
4.2 Global Pneumonia Vaccine Revenue by Type (2018-2034)
4.2.1 Global Pneumonia Vaccine Revenue by Type (2018-2023)
4.2.2 Global Pneumonia Vaccine Revenue by Type (2024-2034)
4.2.3 Global Pneumonia Vaccine Revenue Market Share by Type (2018-2034)
4.3 Global Pneumonia Vaccine Price by Type (2018-2034)
5 Segment by Application
5.1 Global Pneumonia Vaccine Sales by Application (2018-2034)
5.1.1 Global Pneumonia Vaccine Sales by Application (2018-2023)
5.1.2 Global Pneumonia Vaccine Sales by Application (2024-2034)
5.1.3 Global Pneumonia Vaccine Sales Market Share by Application (2018-2034)
5.2 Global Pneumonia Vaccine Revenue by Application (2018-2034)
5.2.1 Global Pneumonia Vaccine Revenue by Application (2018-2023)
5.2.2 Global Pneumonia Vaccine Revenue by Application (2024-2034)
5.2.3 Global Pneumonia Vaccine Revenue Market Share by Application (2018-2034)
5.3 Global Pneumonia Vaccine Price by Application (2018-2034)
6 Key Companies Profiled
6.1 Pfizer Inc.
6.1.1 Pfizer Inc. Corporation Information
6.1.2 Pfizer Inc. Description and Business Overview
6.1.3 Pfizer Inc. Pneumonia Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Pfizer Inc. Pneumonia Vaccine Product Portfolio
6.1.5 Pfizer Inc. Recent Developments/Updates
6.2 Glaxosmithkline Plc.
6.2.1 Glaxosmithkline Plc. Corporation Information
6.2.2 Glaxosmithkline Plc. Description and Business Overview
6.2.3 Glaxosmithkline Plc. Pneumonia Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Glaxosmithkline Plc. Pneumonia Vaccine Product Portfolio
6.2.5 Glaxosmithkline Plc. Recent Developments/Updates
6.3 Merck & Co., Inc.
6.3.1 Merck & Co., Inc. Corporation Information
6.3.2 Merck & Co., Inc. Description and Business Overview
6.3.3 Merck & Co., Inc. Pneumonia Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Merck & Co., Inc. Pneumonia Vaccine Product Portfolio
6.3.5 Merck & Co., Inc. Recent Developments/Updates
6.4 Sanofi Pasteur
6.4.1 Sanofi Pasteur Corporation Information
6.4.2 Sanofi Pasteur Description and Business Overview
6.4.3 Sanofi Pasteur Pneumonia Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Sanofi Pasteur Pneumonia Vaccine Product Portfolio
6.4.5 Sanofi Pasteur Recent Developments/Updates
6.5 Serum Institute of India Pvt. Ltd.
6.5.1 Serum Institute of India Pvt. Ltd. Corporation Information
6.5.2 Serum Institute of India Pvt. Ltd. Description and Business Overview
6.5.3 Serum Institute of India Pvt. Ltd. Pneumonia Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Serum Institute of India Pvt. Ltd. Pneumonia Vaccine Product Portfolio
6.5.5 Serum Institute of India Pvt. Ltd. Recent Developments/Updates
6.6 Johnson & Johnson
6.6.1 Johnson & Johnson Corporation Information
6.6.2 Johnson & Johnson Description and Business Overview
6.6.3 Johnson & Johnson Pneumonia Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Johnson & Johnson Pneumonia Vaccine Product Portfolio
6.6.5 Johnson & Johnson Recent Developments/Updates
6.7 Astellas Pharma Inc.
6.6.1 Astellas Pharma Inc. Corporation Information
6.6.2 Astellas Pharma Inc. Description and Business Overview
6.6.3 Astellas Pharma Inc. Pneumonia Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Astellas Pharma Inc. Pneumonia Vaccine Product Portfolio
6.7.5 Astellas Pharma Inc. Recent Developments/Updates
6.8 Astrazeneca Plc.
6.8.1 Astrazeneca Plc. Corporation Information
6.8.2 Astrazeneca Plc. Description and Business Overview
6.8.3 Astrazeneca Plc. Pneumonia Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Astrazeneca Plc. Pneumonia Vaccine Product Portfolio
6.8.5 Astrazeneca Plc. Recent Developments/Updates
6.9 CSL Limited
6.9.1 CSL Limited Corporation Information
6.9.2 CSL Limited Description and Business Overview
6.9.3 CSL Limited Pneumonia Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.9.4 CSL Limited Pneumonia Vaccine Product Portfolio
6.9.5 CSL Limited Recent Developments/Updates
6.10 Emergent Biosolutions
6.10.1 Emergent Biosolutions Corporation Information
6.10.2 Emergent Biosolutions Description and Business Overview
6.10.3 Emergent Biosolutions Pneumonia Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Emergent Biosolutions Pneumonia Vaccine Product Portfolio
6.10.5 Emergent Biosolutions Recent Developments/Updates
6.11 Walvax Biotechnology
6.11.1 Walvax Biotechnology Corporation Information
6.11.2 Walvax Biotechnology Pneumonia Vaccine Description and Business Overview
6.11.3 Walvax Biotechnology Pneumonia Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Walvax Biotechnology Pneumonia Vaccine Product Portfolio
6.11.5 Walvax Biotechnology Recent Developments/Updates
6.12 Royal (Wuxi) Bio-Pharmaceutical
6.12.1 Royal (Wuxi) Bio-Pharmaceutical Corporation Information
6.12.2 Royal (Wuxi) Bio-Pharmaceutical Pneumonia Vaccine Description and Business Overview
6.12.3 Royal (Wuxi) Bio-Pharmaceutical Pneumonia Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Royal (Wuxi) Bio-Pharmaceutical Pneumonia Vaccine Product Portfolio
6.12.5 Royal (Wuxi) Bio-Pharmaceutical Recent Developments/Updates
6.13 Zhifei Biologic
6.13.1 Zhifei Biologic Corporation Information
6.13.2 Zhifei Biologic Pneumonia Vaccine Description and Business Overview
6.13.3 Zhifei Biologic Pneumonia Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Zhifei Biologic Pneumonia Vaccine Product Portfolio
6.13.5 Zhifei Biologic Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Pneumonia Vaccine Industry Chain Analysis
7.2 Pneumonia Vaccine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Pneumonia Vaccine Production Mode & Process
7.4 Pneumonia Vaccine Sales and Marketing
7.4.1 Pneumonia Vaccine Sales Channels
7.4.2 Pneumonia Vaccine Distributors
7.5 Pneumonia Vaccine Customers
8 Pneumonia Vaccine Market Dynamics
8.1 Pneumonia Vaccine Industry Trends
8.2 Pneumonia Vaccine Market Drivers
8.3 Pneumonia Vaccine Market Challenges
8.4 Pneumonia Vaccine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Figure

List of Tables
Table 1. Global Pneumonia Vaccine Market Value Comparison by Type (2024-2034) & (US$ Million)
Table 2. Global Pneumonia Vaccine Market Value Comparison by Application (2024-2034) & (US$ Million)
Table 3. Global Pneumonia Vaccine Market Competitive Situation by Manufacturers in 2024
Table 4. Global Pneumonia Vaccine Sales (K Doses) of Key Manufacturers (2018-2023)
Table 5. Global Pneumonia Vaccine Sales Market Share by Manufacturers (2018-2023)
Table 6. Global Pneumonia Vaccine Revenue (US$ Million) by Manufacturers (2018-2023)
Table 7. Global Pneumonia Vaccine Revenue Share by Manufacturers (2018-2023)
Table 8. Global Market Pneumonia Vaccine Average Price (USD/Dose) of Key Manufacturers (2018-2023)
Table 9. Global Key Players of Pneumonia Vaccine, Industry Ranking, 2021 VS 2024 VS 2023
Table 10. Global Key Manufacturers of Pneumonia Vaccine, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Pneumonia Vaccine, Product Type & Application
Table 12. Global Key Manufacturers of Pneumonia Vaccine, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Pneumonia Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pneumonia Vaccine as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Pneumonia Vaccine Market Size by Region (US$ Million): 2018 VS 2024 VS 2034
Table 17. Global Pneumonia Vaccine Sales by Region (2018-2023) & (K Doses)
Table 18. Global Pneumonia Vaccine Sales Market Share by Region (2018-2023)
Table 19. Global Pneumonia Vaccine Sales by Region (2024-2034) & (K Doses)
Table 20. Global Pneumonia Vaccine Sales Market Share by Region (2024-2034)
Table 21. Global Pneumonia Vaccine Revenue by Region (2018-2023) & (US$ Million)
Table 22. Global Pneumonia Vaccine Revenue Market Share by Region (2018-2023)
Table 23. Global Pneumonia Vaccine Revenue by Region (2024-2034) & (US$ Million)
Table 24. Global Pneumonia Vaccine Revenue Market Share by Region (2024-2034)
Table 25. North America Pneumonia Vaccine Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 26. North America Pneumonia Vaccine Sales by Country (2018-2023) & (K Doses)
Table 27. North America Pneumonia Vaccine Sales by Country (2024-2034) & (K Doses)
Table 28. North America Pneumonia Vaccine Revenue by Country (2018-2023) & (US$ Million)
Table 29. North America Pneumonia Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 30. Europe Pneumonia Vaccine Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 31. Europe Pneumonia Vaccine Sales by Country (2018-2023) & (K Doses)
Table 32. Europe Pneumonia Vaccine Sales by Country (2024-2034) & (K Doses)
Table 33. Europe Pneumonia Vaccine Revenue by Country (2018-2023) & (US$ Million)
Table 34. Europe Pneumonia Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 35. Asia Pacific Pneumonia Vaccine Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 36. Asia Pacific Pneumonia Vaccine Sales by Region (2018-2023) & (K Doses)
Table 37. Asia Pacific Pneumonia Vaccine Sales by Region (2024-2034) & (K Doses)
Table 38. Asia Pacific Pneumonia Vaccine Revenue by Region (2018-2023) & (US$ Million)
Table 39. Asia Pacific Pneumonia Vaccine Revenue by Region (2024-2034) & (US$ Million)
Table 40. Latin America Pneumonia Vaccine Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 41. Latin America Pneumonia Vaccine Sales by Country (2018-2023) & (K Doses)
Table 42. Latin America Pneumonia Vaccine Sales by Country (2024-2034) & (K Doses)
Table 43. Latin America Pneumonia Vaccine Revenue by Country (2018-2023) & (US$ Million)
Table 44. Latin America Pneumonia Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 45. Middle East & Africa Pneumonia Vaccine Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 46. Middle East & Africa Pneumonia Vaccine Sales by Country (2018-2023) & (K Doses)
Table 47. Middle East & Africa Pneumonia Vaccine Sales by Country (2024-2034) & (K Doses)
Table 48. Middle East & Africa Pneumonia Vaccine Revenue by Country (2018-2023) & (US$ Million)
Table 49. Middle East & Africa Pneumonia Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 50. Global Pneumonia Vaccine Sales (K Doses) by Type (2018-2023)
Table 51. Global Pneumonia Vaccine Sales (K Doses) by Type (2024-2034)
Table 52. Global Pneumonia Vaccine Sales Market Share by Type (2018-2023)
Table 53. Global Pneumonia Vaccine Sales Market Share by Type (2024-2034)
Table 54. Global Pneumonia Vaccine Revenue (US$ Million) by Type (2018-2023)
Table 55. Global Pneumonia Vaccine Revenue (US$ Million) by Type (2024-2034)
Table 56. Global Pneumonia Vaccine Revenue Market Share by Type (2018-2023)
Table 57. Global Pneumonia Vaccine Revenue Market Share by Type (2024-2034)
Table 58. Global Pneumonia Vaccine Price (USD/Dose) by Type (2018-2023)
Table 59. Global Pneumonia Vaccine Price (USD/Dose) by Type (2024-2034)
Table 60. Global Pneumonia Vaccine Sales (K Doses) by Application (2018-2023)
Table 61. Global Pneumonia Vaccine Sales (K Doses) by Application (2024-2034)
Table 62. Global Pneumonia Vaccine Sales Market Share by Application (2018-2023)
Table 63. Global Pneumonia Vaccine Sales Market Share by Application (2024-2034)
Table 64. Global Pneumonia Vaccine Revenue (US$ Million) by Application (2018-2023)
Table 65. Global Pneumonia Vaccine Revenue (US$ Million) by Application (2024-2034)
Table 66. Global Pneumonia Vaccine Revenue Market Share by Application (2018-2023)
Table 67. Global Pneumonia Vaccine Revenue Market Share by Application (2024-2034)
Table 68. Global Pneumonia Vaccine Price (USD/Dose) by Application (2018-2023)
Table 69. Global Pneumonia Vaccine Price (USD/Dose) by Application (2024-2034)
Table 70. Pfizer Inc. Corporation Information
Table 71. Pfizer Inc. Description and Business Overview
Table 72. Pfizer Inc. Pneumonia Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2023)
Table 73. Pfizer Inc. Pneumonia Vaccine Product
Table 74. Pfizer Inc. Recent Developments/Updates
Table 75. Glaxosmithkline Plc. Corporation Information
Table 76. Glaxosmithkline Plc. Description and Business Overview
Table 77. Glaxosmithkline Plc. Pneumonia Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2023)
Table 78. Glaxosmithkline Plc. Pneumonia Vaccine Product
Table 79. Glaxosmithkline Plc. Recent Developments/Updates
Table 80. Merck & Co., Inc. Corporation Information
Table 81. Merck & Co., Inc. Description and Business Overview
Table 82. Merck & Co., Inc. Pneumonia Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2023)
Table 83. Merck & Co., Inc. Pneumonia Vaccine Product
Table 84. Merck & Co., Inc. Recent Developments/Updates
Table 85. Sanofi Pasteur Corporation Information
Table 86. Sanofi Pasteur Description and Business Overview
Table 87. Sanofi Pasteur Pneumonia Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2023)
Table 88. Sanofi Pasteur Pneumonia Vaccine Product
Table 89. Sanofi Pasteur Recent Developments/Updates
Table 90. Serum Institute of India Pvt. Ltd. Corporation Information
Table 91. Serum Institute of India Pvt. Ltd. Description and Business Overview
Table 92. Serum Institute of India Pvt. Ltd. Pneumonia Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2023)
Table 93. Serum Institute of India Pvt. Ltd. Pneumonia Vaccine Product
Table 94. Serum Institute of India Pvt. Ltd. Recent Developments/Updates
Table 95. Johnson & Johnson Corporation Information
Table 96. Johnson & Johnson Description and Business Overview
Table 97. Johnson & Johnson Pneumonia Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2023)
Table 98. Johnson & Johnson Pneumonia Vaccine Product
Table 99. Johnson & Johnson Recent Developments/Updates
Table 100. Astellas Pharma Inc. Corporation Information
Table 101. Astellas Pharma Inc. Description and Business Overview
Table 102. Astellas Pharma Inc. Pneumonia Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2023)
Table 103. Astellas Pharma Inc. Pneumonia Vaccine Product
Table 104. Astellas Pharma Inc. Recent Developments/Updates
Table 105. Astrazeneca Plc. Corporation Information
Table 106. Astrazeneca Plc. Description and Business Overview
Table 107. Astrazeneca Plc. Pneumonia Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2023)
Table 108. Astrazeneca Plc. Pneumonia Vaccine Product
Table 109. Astrazeneca Plc. Recent Developments/Updates
Table 110. CSL Limited Corporation Information
Table 111. CSL Limited Description and Business Overview
Table 112. CSL Limited Pneumonia Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2023)
Table 113. CSL Limited Pneumonia Vaccine Product
Table 114. CSL Limited Recent Developments/Updates
Table 115. Emergent Biosolutions Corporation Information
Table 116. Emergent Biosolutions Description and Business Overview
Table 117. Emergent Biosolutions Pneumonia Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2023)
Table 118. Emergent Biosolutions Pneumonia Vaccine Product
Table 119. Emergent Biosolutions Recent Developments/Updates
Table 120. Walvax Biotechnology Corporation Information
Table 121. Walvax Biotechnology Description and Business Overview
Table 122. Walvax Biotechnology Pneumonia Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2023)
Table 123. Walvax Biotechnology Pneumonia Vaccine Product
Table 124. Walvax Biotechnology Recent Developments/Updates
Table 125. Royal (Wuxi) Bio-Pharmaceutical Corporation Information
Table 126. Royal (Wuxi) Bio-Pharmaceutical Description and Business Overview
Table 127. Royal (Wuxi) Bio-Pharmaceutical Pneumonia Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2023)
Table 128. Royal (Wuxi) Bio-Pharmaceutical Pneumonia Vaccine Product
Table 129. Royal (Wuxi) Bio-Pharmaceutical Recent Developments/Updates
Table 130. Zhifei Biologic Corporation Information
Table 131. Zhifei Biologic Description and Business Overview
Table 132. Zhifei Biologic Pneumonia Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2018-2023)
Table 133. Zhifei Biologic Pneumonia Vaccine Product
Table 134. Zhifei Biologic Recent Developments/Updates
Table 135. Key Raw Materials Lists
Table 136. Raw Materials Key Suppliers Lists
Table 137. Pneumonia Vaccine Distributors List
Table 138. Pneumonia Vaccine Customers List
Table 139. Pneumonia Vaccine Market Trends
Table 140. Pneumonia Vaccine Market Drivers
Table 141. Pneumonia Vaccine Market Challenges
Table 142. Pneumonia Vaccine Market Restraints
Table 143. Research Programs/Design for This Report
Table 144. Key Data Information from Secondary Sources
Table 145. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Pneumonia Vaccine
Figure 2. Global Pneumonia Vaccine Market Value Comparison by Type (2024-2034) & (US$ Million)
Figure 3. Global Pneumonia Vaccine Market Share by Type in 2024 & 2034
Figure 4. Pneumococcal Conjugate Vaccine (PCV13) Product Picture
Figure 5. Pneumococcal Polysaccharide Vaccine (PPSV23) Product Picture
Figure 6. Other Product Picture
Figure 7. Global Pneumonia Vaccine Market Value Comparison by Application (2024-2034) & (US$ Million)
Figure 8. Global Pneumonia Vaccine Market Share by Application in 2024 & 2034
Figure 9. Pneumonia
Figure 10. Meningitis
Figure 11. Sepsis
Figure 12. Global Pneumonia Vaccine Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 13. Global Pneumonia Vaccine Market Size (2018-2034) & (US$ Million)
Figure 14. Global Pneumonia Vaccine Sales (2018-2034) & (K Doses)
Figure 15. Global Pneumonia Vaccine Average Price (USD/Dose) & (2018-2034)
Figure 16. Pneumonia Vaccine Report Years Considered
Figure 17. Pneumonia Vaccine Sales Share by Manufacturers in 2024
Figure 18. Global Pneumonia Vaccine Revenue Share by Manufacturers in 2024
Figure 19. The Global 5 and 10 Largest Pneumonia Vaccine Players: Market Share by Revenue in 2024
Figure 20. Pneumonia Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2024
Figure 21. Global Pneumonia Vaccine Market Size by Region (US$ Million): 2018 VS 2024 VS 2034
Figure 22. North America Pneumonia Vaccine Sales Market Share by Country (2018-2034)
Figure 23. North America Pneumonia Vaccine Revenue Market Share by Country (2018-2034)
Figure 24. U.S. Pneumonia Vaccine Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 25. Canada Pneumonia Vaccine Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 26. Europe Pneumonia Vaccine Sales Market Share by Country (2018-2034)
Figure 27. Europe Pneumonia Vaccine Revenue Market Share by Country (2018-2034)
Figure 28. Germany Pneumonia Vaccine Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 29. France Pneumonia Vaccine Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 30. U.K. Pneumonia Vaccine Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 31. Italy Pneumonia Vaccine Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 32. Russia Pneumonia Vaccine Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 33. Asia Pacific Pneumonia Vaccine Sales Market Share by Region (2018-2034)
Figure 34. Asia Pacific Pneumonia Vaccine Revenue Market Share by Region (2018-2034)
Figure 35. China Pneumonia Vaccine Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 36. Japan Pneumonia Vaccine Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 37. South Korea Pneumonia Vaccine Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 38. India Pneumonia Vaccine Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 39. Australia Pneumonia Vaccine Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 40. Taiwan Pneumonia Vaccine Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 41. Indonesia Pneumonia Vaccine Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 42. Thailand Pneumonia Vaccine Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 43. Malaysia Pneumonia Vaccine Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 44. Philippines Pneumonia Vaccine Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 45. Latin America Pneumonia Vaccine Sales Market Share by Country (2018-2034)
Figure 46. Latin America Pneumonia Vaccine Revenue Market Share by Country (2018-2034)
Figure 47. Mexico Pneumonia Vaccine Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 48. Brazil Pneumonia Vaccine Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 49. Argentina Pneumonia Vaccine Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 50. Middle East & Africa Pneumonia Vaccine Sales Market Share by Country (2018-2034)
Figure 51. Middle East & Africa Pneumonia Vaccine Revenue Market Share by Country (2018-2034)
Figure 52. Turkey Pneumonia Vaccine Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 53. Saudi Arabia Pneumonia Vaccine Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 54. U.A.E Pneumonia Vaccine Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 55. Global Sales Market Share of Pneumonia Vaccine by Type (2018-2034)
Figure 56. Global Revenue Market Share of Pneumonia Vaccine by Type (2018-2034)
Figure 57. Global Pneumonia Vaccine Price (USD/Dose) by Type (2018-2034)
Figure 58. Global Sales Market Share of Pneumonia Vaccine by Application (2018-2034)
Figure 59. Global Revenue Market Share of Pneumonia Vaccine by Application (2018-2034)
Figure 60. Global Pneumonia Vaccine Price (USD/Dose) by Application (2018-2034)
Figure 61. Pneumonia Vaccine Value Chain
Figure 62. Pneumonia Vaccine Production Process
Figure 63. Channels of Distribution (Direct Vs Distribution)
Figure 64. Distributors Profiles
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed